Advertisement

Sonoma Pharmaceuticals, Inc. SNOA

Set alert

Price alert · SNOA

All alert types
1.10 USD -0.10 -8.33%

At close · Oct 30

1.10 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
1.07 × 2
Ask
1.10 × 2
1.07 Day range 1.17
1.01 52-week range 3.95
YTD
-69.78%
1 year
-72.15%
Open
1.16
Prev close
1.20
Mkt cap
5.27M
Vol
85.81K
Avg vol
106.86K
EPS
-1.22
P/E
0.00
Div yield
0.00%
More statistics
Low
1.07
High
1.17
Forward P/E
-1.49
Beta
1.38
Short ratio
0.22
Inst. own
2.42%
Dividend
0.00
Ex-div date
Earnings
Feb 13, 2025
50-d avg
2.82
200-d avg
3.79
1y target
19.50

2Y chart

Chart tools
Interval

Events in this range
  • Nov 7, 2024Earnings: -0.59; estimate 0; surprise —%
  • Feb 13, 2025Earnings: —; estimate 0; surprise —%
Signals (92)
NameDateAgo
MACD: Buy SignalOct 28, 20263 days ago
SMA: BearishOct 1, 20261 month ago
SMA: BullishSep 30, 20261 month ago
SMA: BearishSep 23, 20261 month ago
SMA: BullishSep 22, 20261 month ago
SMA: BearishSep 21, 20261 month ago
SMA: BearishSep 16, 20261 month ago
MACD: Sell SignalAug 28, 20262 months ago
SMA: BullishAug 6, 20262 months ago
MACD: Buy SignalAug 6, 20262 months ago
SMA: BearishAug 5, 20262 months ago
SMA: BullishAug 4, 20262 months ago
MACD: Sell SignalJul 20, 20263 months ago
SMA: BullishJun 30, 20264 months ago
RSI: OversoldMay 18, 20265 months ago
MACD: Buy SignalMay 12, 20265 months ago
RSI: OversoldApr 24, 20266 months ago
MACD: Sell SignalApr 23, 20266 months ago
SMA: BearishApr 21, 20266 months ago
SMA: BullishApr 20, 20266 months ago
MACD: Buy SignalApr 1, 20267 months ago
RSI: OversoldMar 30, 20267 months ago
MACD: Sell SignalMar 26, 20267 months ago
RSI: OversoldMar 26, 20267 months ago
MACD: Buy SignalMar 19, 20267 months ago
MACD: Sell SignalMar 6, 20267 months ago
RSI: OversoldMar 5, 20268 months ago
MACD: Buy SignalFeb 23, 20268 months ago
RSI: OversoldFeb 5, 20268 months ago
SMA: BearishJan 12, 20269 months ago
SMA: BearishJan 12, 20269 months ago
MACD: Sell SignalJan 12, 20269 months ago
SMA: BullishDec 30, 202510 months ago
SMA: BearishDec 29, 202510 months ago
SMA: BullishDec 24, 202510 months ago
SMA: BearishDec 23, 202510 months ago
SMA: BullishDec 22, 202510 months ago
SMA: BullishDec 17, 202510 months ago
SMA: BearishDec 15, 202510 months ago
SMA: BearishDec 11, 202510 months ago
SMA: BullishDec 10, 202510 months ago
SMA: BullishDec 4, 202511 months ago
MACD: Buy SignalDec 4, 202511 months ago
SMA: BearishNov 19, 202511 months ago
MACD: Sell SignalNov 4, 202512 months ago
MACD: Buy SignalOct 29, 20251 year ago
MACD: Sell SignalOct 17, 20251 year ago
SMA: BearishOct 10, 20251 year ago
MACD: Buy SignalOct 7, 20251 year ago
SMA: BullishOct 6, 20251 year ago
SMA: BullishSep 24, 20251 year ago
SMA: BearishSep 23, 20251 year ago
MACD: Sell SignalAug 29, 20251 year ago
SMA: BullishAug 14, 20251 year ago
MACD: Buy SignalAug 14, 20251 year ago
RSI: OverboughtAug 14, 20251 year ago
SMA: BearishJul 29, 20251 year ago
MACD: Sell SignalJul 28, 20251 year ago
SMA: BullishJul 10, 20251 year ago
RSI: OverboughtJul 10, 20251 year ago
MACD: Buy SignalJul 7, 20251 year ago
SMA: BearishJun 16, 20251 year ago
MACD: Sell SignalJun 6, 20251 year ago
MACD: Buy SignalJun 2, 20251 year ago
MACD: Sell SignalMay 7, 20251 year ago
RSI: OverboughtApr 25, 20251 year ago
SMA: BullishApr 23, 20251 year ago
RSI: OverboughtApr 23, 20251 year ago
MACD: Buy SignalApr 15, 20251 year ago
SMA: BearishMar 28, 20251 year ago
MACD: Sell SignalMar 27, 20251 year ago
RSI: OverboughtMar 17, 20251 year ago
RSI: OverboughtMar 11, 20251 year ago
SMA: BullishMar 10, 20251 year ago
MACD: Buy SignalMar 10, 20251 year ago
RSI: OversoldMar 7, 20251 year ago
RSI: OversoldMar 3, 20251 year ago
RSI: OversoldFeb 27, 20251 year ago
MACD: Sell SignalFeb 10, 20251 year ago
MACD: Buy SignalFeb 4, 20251 year ago
MACD: Sell SignalFeb 3, 20251 year ago
SMA: BearishJan 29, 20251 year ago
SMA: BullishJan 28, 20251 year ago
SMA: BearishJan 27, 20251 year ago
SMA: BullishJan 24, 20251 year ago
MACD: Buy SignalJan 23, 20251 year ago
MACD: Sell SignalJan 22, 20251 year ago
MACD: Buy SignalJan 21, 20251 year ago
MACD: Sell SignalJan 10, 20251 year ago
MACD: Buy SignalJan 6, 20251 year ago
MACD: Sell SignalJan 3, 20251 year ago
MACD: Buy SignalDec 27, 20241 year ago

Key statistics

Market cap
3.59M
Enterprise value
569.36K
Trailing P/E
0.00
Forward P/E
-1.49
PEG ratio
0.00
Price / sales
0.28
Price / book
0.34
EPS (TTM)
-0.99
Beta
1.38
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-35.91%
Revenue (TTM)
12.70M
Revenue growth
-1.10%
Free cash flow
-1.70M
Total cash
2.59M
Total debt
420.00K
Return on equity
-74.65%
Shares outstanding
1.34M
Short % of float
6.06%
50-day average
2.82
200-day average
3.79

Analyst view

Consensus: none

Price target (mean) 19.50 +1672.7% upside
Target (low)
17.00
Target (mean)
19.50
Target (high)
22.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Feb 13, 2025

Expected Feb 13, 2025. Consensus EPS estimate -0.60.

Earnings history

Financials — quick view

All financials
SNOA Revenue — quarterly 6.41M
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
SNOA Net income — quarterly -330.00K
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
SNOA EPS — quarterly -0.09
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026

Earnings

SNOA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 13, 2025Dec 1, 20240.00———
Nov 7, 2024Sep 1, 20240.00-0.59——
Aug 8, 2024Jun 1, 20240.00-1.40——
Jun 17, 2024Mar 1, 20240.00-1.40——
Feb 8, 2024Dec 1, 20230.00-1.20——
Nov 13, 2023Sep 1, 20230.00-4.00——

Upgrades / downgrades

SNOA analyst upgrades and downgrades
DateFirmActionFromTo
Sep 5, 2023Ladenburg Thalmanninit—Buy
Mar 6, 2018Maxim GroupdownBuyHold
Dec 28, 2017Benchmarkinit—Speculative Buy
Nov 10, 2017Maxim Groupmain—Buy

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States

News

Your note

Sign in to keep a note on SNOA — it syncs with the Stock Master app.

Insider holders

SNOA insider holders
InsiderRelationLatest transactionDateShares held
DAL POGGETTO JOHNOfficerStock Award(Grant)Jun 19, 202415,000
DVONCH JEROME JChief Financial OfficerStock Award(Grant)Jun 19, 202484,595
THORNTON BRUCEOfficerStock Award(Grant)Jun 19, 2024154,411
TROMBLY AMY MOSSChief Executive OfficerStock Award(Grant)Jun 19, 2024153,586

Institution ownership

SNOA institution ownership
Holder% heldSharesValueReported
UBS Group AG0.95%12,73034.12KSep 29, 2024
Ground Swell Capital, LLC0.78%10,40027.87KSep 29, 2024
Tower Research Capital LLC (TRC)0.31%4,14111.10KSep 29, 2024
Citigroup Inc.0.01%180482Sep 29, 2024
JP Morgan Chase & Company0.01%138369Sep 29, 2024
Blackrock Inc.0.01%113302Sep 29, 2024

Fund ownership

SNOA fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.40%5,34214.32KOct 30, 2024
Fidelity Total Market Index Fund0.19%2,5286.78KOct 30, 2024
Fidelity Series Total Market Index Fund0.14%1,8815.04KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.02%248664Oct 30, 2024
Vanguard Extended Market Index Fund0.01%190509Sep 29, 2024
Advertisement